Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Atrium Therapeutics, Inc. - Common Stock
(NQ:
RNA
)
13.45
-0.20 (-1.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atrium Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
↗
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 07, 2024
Via
Benzinga
Why Avidity Biosciences Zoomed to a 12% Gain This Week
↗
October 04, 2024
The company's most promising pipeline program can continue unabated.
Via
The Motley Fool
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
↗
September 24, 2024
Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular...
Via
Benzinga
Unveiling 7 Analyst Insights On Avidity Biosciences
↗
September 16, 2024
Via
Benzinga
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)
↗
August 28, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On Avidity Biosciences
↗
August 12, 2024
Via
Benzinga
(RNA) - Analyzing Avidity Biosciences's Short Interest
↗
June 20, 2024
Via
Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
↗
September 09, 2024
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in...
Via
Benzinga
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
August 19, 2024
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.
Via
MarketBeat
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
↗
August 09, 2024
RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
↗
August 09, 2024
Via
Benzinga
Chart Of The Day: Avidity Biosciences - Something's Up?
↗
June 14, 2024
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
Via
Talk Markets
A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts
↗
June 10, 2024
Via
Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
↗
August 09, 2024
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.
Via
Investor's Business Daily
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
↗
July 24, 2024
These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market.
Via
InvestorPlace
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
↗
July 23, 2024
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.
Via
The Motley Fool
Topics
Economy
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
↗
July 18, 2024
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via
Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
↗
July 01, 2024
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged.
Via
Benzinga
Topics
ETFs
Trading SMID Biotech Stocks In A Volatile Market
↗
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
↗
June 16, 2024
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry.
Via
Benzinga
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
↗
June 14, 2024
Via
Benzinga
Crude Oil Moves Higher; Vera Bradley Shares Slide
↗
June 12, 2024
Via
Benzinga
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
June 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
June 12, 2024
Via
Benzinga
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher
↗
June 12, 2024
Via
Benzinga
Why Avidity Biosciences Shares Are Trading Higher Wednesday
↗
June 12, 2024
The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran.
Via
Benzinga
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
↗
June 12, 2024
Via
Benzinga
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point
↗
June 12, 2024
The company is working on a treatment for a rare form of muscular dystrophy.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
June 12, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
